Upon joining the study, an initial assessment will be conducted to confirm eligibility. This includes checking the **Eastern Cooperative Oncology Group (ECOG) performance status**, ensuring a life expectancy of at least 12 weeks, and verifying adequate organ and bone marrow function.

Body weight will be measured to ensure it is at least 35 kilograms. A review of medical history will confirm the absence of specific genetic mutations and the presence of at least one measurable tumor lesion.

The treatment phase begins with the administration of **volrustomig** in combination with other anticancer drugs. The specific medications include **pemetrexed**, **mycophenolate mofetil**, **carboplatin**, and **infliximab**.

These medications are administered through different methods: **intravenous infusion** for pemetrexed, carboplatin, and infliximab, and **oral capsules** for mycophenolate mofetil.

The treatment will continue over a specified period, with regular administration of the medications. The frequency and dosage will be determined by the study protocol and the medical team overseeing the trial.

Participants will receive regular monitoring to assess the safety and tolerability of the treatment, as well as its effectiveness in reducing tumor size.

Throughout the trial, regular assessments will be conducted to monitor health status and treatment response. This includes blood tests, imaging scans, and other necessary evaluations.

The primary goal is to ensure the safety of the treatment and to measure its impact on tumor growth.

Upon completion of the treatment phase, a final assessment will be conducted to evaluate the overall response to the treatment.

Participants will be informed of the results and any further steps or follow-up care that may be necessary.